Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NaF PET-CT for Thromboembolic Stroke Origin
NCT06961604Phase 1Not yet recruiting
- Sponsor
- Atlantic Health System
- Start
- Jun 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sodium fluoride f-18 in thromboembolic stroke, sponsored by Atlantic Health System. Primary endpoint: Culprit lesion at 14 days. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
sodium fluoride f-18
03
Conditions
thromboembolic stroke
Beyond the preview
Go deeper on NCT06961604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06961604.